https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8085845/
the above review article was part of BK's WSJ's article and I think it does a really good job of highlighting a lot of the chemotherapeutic and targeted/selective anti-cancer therapies' cardiotoxicity side effects.
The article provide excellent lists of the different chemo and targeted/selective agents which cause cardiotoxicity. But FTO inhibition is not on the list and some are not covered by Doan Ngo's research paper https://www.sciencedirect.com/science/article/pii/S144395062400043X
the targeted anti-cancer agents are some of the latest, and maybe greatest, modern anti-cancer technology but they still have cardiotoxicity:
- HER-2 inhibitors
- Immune checkpoint inhibitors (including PD-1, eg. Keytruda, one of the best selling cancer drugs in the world)
- Small molecule TKIs and VEGF-inhibitors
- Proteasome inhibitors
- CART-T cells
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8085845/the above...
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.26 |
Change
0.040(3.28%) |
Mkt cap ! $209.4M | |||
| Open | High | Low | Value | Volume |
| $1.22 | $1.27 | $1.19 | $119.8K | 97.24K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1526 | $1.21 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.26 | 1986 | 1 |
View Market Depth
| Last trade - 16.10pm 08/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.23 |
Change
0.040 ( 2.94 %) |
||||
| Open | High | Low | Volume | ||
| $1.22 | $1.27 | $1.20 | 20698 | ||
| Last updated 15.58pm 08/05/2024 ? | |||||
| RAC (ASX) Chart |